| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2017-12-22 |
| タイトル |
|
|
タイトル |
Phase I/II study of alectinib in lung cancer with RET fusion gene: Study protocol |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| ID登録 |
|
|
ID登録 |
10.24517/00049515 |
|
ID登録タイプ |
JaLC |
| 著者 |
Takeuchi, Shinji
Murayama, Toshinori
Yoshimura, Kenichi
Kawakami, Takahiro
Takahara, Shizuko
Imai, Yasuhito
Kuribayashi, Yoshikazu
Nagase, Katsuhiko
Goto, Koichi
Nishio, Makoto
Hasegawa, Yoshinori
Satouchi, Miyako
Kiura, Katsuyuki
Seto, Takashi
Yano, Seiji
|
| 著者別表示 |
竹内, 伸司
村山, 敏典
吉村, 健一
川上, 貴裕
髙原, 志津子
今井, 康人
栗林, 義和
長瀬, 克彦
矢野, 聖二
|
| 提供者所属 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
金沢大学附属病院がんセンター |
| 書誌情報 |
Journal of Medical Investigation
巻 64,
号 3-4,
p. 317-320,
発行日 2017
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1343-1420 |
| NCID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA11166929 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.2152/jmi.64.317 |
| 出版者 |
|
|
出版者 |
The University of Tokushima Faculty of Medicine |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: The rearranged during transfection (RET) fusion gene was discovered as a driver on-cogene in 1-2% of non-small cell lung cancers (NSCLCs). Alectinib is an approved anaplastic lymphoma kinase (ALK) inhibitor that may also be effective for RET fusion-positive NSCLC. Methods/Design: RET fusion-positive NSCLC patients treated with at least one regimen of chemotherapy are being recruited. In step 1, alectinib (600 or 450 mg, twice daily) will be administered following a 3+3 design. The primary endpoint is safety. In step 2, alectinib will be administered at the recommended dose (RD) defined by step 1. The primary endpoint is the response rate of RET inhibitor treatment-naïve patients. Conclusion: This is the first study to investigate the safety and preliminary efficacy of alectinib in RET fusion-positive NSCLC patients. If successful, alectinib treatment may lead to substantial and important changes in the management of NSCLC with RET fusion genes. © 2017, University of Tokushima. All rights reserved. |
| 権利 |
|
|
権利情報 |
Copyright © The University of Tokushima Faculty of Medicine | 許可を得て登録 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 関連URI |
|
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
http://www.tokushima-u.ac.jp/med/ |
|
|
関連名称 |
http://www.tokushima-u.ac.jp/med/ |
| 関連URI |
|
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
https://www.jstage.jst.go.jp/browse/jmi/-char/en |
|
|
関連名称 |
https://www.jstage.jst.go.jp/browse/jmi/-char/en |
HO-PR-TAKEUCHI-S-317.pdf (184.0 kB)
.png)
